Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Here's How Vertex Pharmaceuticals Beat Expectations in Q1

TheMotleyFool

0 0

Here's How Vertex Pharmaceuticals Beat Expectations in Q1Photo, wide shot, wide-angle lens, Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png

Vertex Pharmaceuticals (NASDAQ: VRTX) is proof that Wall Street doesn't always reward companies with monopolies. It markets the only approved drugs that treat the underlying cause of cystic fibrosis (CF), but the company's shares have fallen 30% from the highs set in 2020.

The big drugmaker announced its first-quarter results after the market closed Thursday. However, the update didn't move the needle much, with the biotech stock moving less than 1% higher in after-hours trading. Here are the highlights of Vertex's Q1 update.

Image source: Getty Images.

Source Fool.com

Like: 0

VRTX

Share